CorMedix Inc. Form 8-K

May 29, 2018

#### **UNITED STATES**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 29, 2018

**CORMEDIX** 

INC.

(Exact Name

of Registrant

as Specified

in Charter)

Delaware 001-34673 20-5894890

(State or Other Jurisdictionof Incorporation) (CommissionFile Number) (IRS EmployerIdentification No.)

400

Connell

Drive,

Suite

5000, 07922

Berkeley

Heights,

NJ

(Address

of

Principal (Zip Code)

Executive

Offices)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

On May 29, 2018, we issued a press release to report the progress on our Lock-It 100 trial data review and to announce the appointment of Paul Chew as a Consultant Advisor CMO.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)

**Exhibits** 

Exhibit No. Description

99.1 Press release dated May 29, 2018.

2

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## CORMEDIX INC.

Date: May 29, 2018 By: /s/ Robert W. Cook

Name: Robert W. Cook Title: Chief Financial Officer

3